In the current economic climate it is important to demonstrate that healthcare resources are being used efficiently. As a consequence, pharmacoeconomic analyses are invaluable for assessing the costeffectiveness of new therapeutic strategies.
T he treatment of coronary heart disease (CHD) places a substantial financial burden on healthcare resources. As a consequence, pharmacoeconomic analyses of management and prevention strategies for CHD are a valuable tool for comparing the cost-effectiveness of new medical interventions, allowing healthcare decision-makers to contain costs by choosing those interventions that are most efficient. However, for healthcare planners and providers to make optimal use of pharmacoeconomic evidence, it is important to understand how these analyses are conducted. Here, the basics of pharmacoeconomics are discussed in relation to two major therapeutic regimens for the prevention of CHD: blood-pressure-lowering therapy and cholesterol-lowering therapy.
GENERAL PRINCIPLES
When treating an illness with a particular therapeutic strategy, cost-effectiveness analyses not only consider the direct costs incurred but also the cost savings (so-called "offsets") that are made after the implementation of that strategy. In other words, such analyses determine the extent to which a given treatment is able to pay for itself through the subsequent offsetting of costs. Clearly, in a condition that has a frequently occurring and costly morbidity (eg, hospital admis-sion, expensive surgical procedure) there is enormous potential to redeem the cost of treatment. Conversely, in a condition characterized by infrequent and inexpensive morbidity there is much less opportunity to offset costs. Thus, a basic principle is that a treatment is least cost-effective where life expectancy is long and morbid events are few and inexpensive. Inevitably, this means that primary prevention strategies are likely to be less cost-effective than secondary prevention strategies.
For a treatment strategy to significantly reduce costs it should have a rapid and substantial impact upon the disease process, ie, it must be highly efficacious. The importance of efficacy of treatment on cost-effectiveness is clearly seen in the area of cholesterol lowering and in the era of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). In some of the older cholesterol lowering trials, a fairly weak effect of treatment was achieved and this was often reflected in the modest reductions in morbid events reported. [1] [2] [3] More recently, with more efficacious cholesterol-lowering drugs, such as the statins, greater reductions in cholesterol have been achieved, resulting in substantial beneficial effects on morbidity occurring within 6 to 12 months of starting therapy. 4 -8 When conducting cost-effectiveness analyses there is a tendency to ignore the indirect costs of treatment. One reason for this may be that direct costs (eg, the cost of a bypass operation or the cost of caring for a patient who has suffered a stroke) are usually quite easy to measure, whereas indirect costs (eg, productivity losses and sickness benefit payments associated with a worker unable to continue employment) are much harder to quantify. Nevertheless, when considering middle-aged people who might have many years of productive life ahead of them, a stroke or a heart attack that prevents work and requires longterm sickness payment can generate indirect costs to the state that might significantly affect the outcome of a cost-effectiveness analysis.
Essentially, the cost-effectiveness of a therapeutic agent can be estimated by balancing the total treatment costs, including additional costs incurred during the posttreatment period, against the total cost savings ( Table 1) . Examples of additional costs might be those resulting from the monitoring of lipid levels after the administration of a cholesterol-lowering agent or those associated with the treatment of drug-attributable adverse events. As already discussed, cost savings are usually most significant when the treatment produces a decrease in morbid events. There are several outcome units that can be used to measure the cost-effectiveness of different therapies. These include cost per life-year gained (LYG); cost per quality-adjusted life-year gained (QALY); and number needed to treat (NNT).
The cost per LYG assesses the benefit of treatment purely in terms of mortality. Quite simply, it can be thought of as the amount of money that must be paid, usually by a country's health service, to extend the life of a patient by 1 year.
It can be argued that a good treatment should also improve, or at the very least maintain, a patient's quality of life. The QALY, therefore, not only measures cost-effectiveness in terms of longevity but also takes into account improvements in lifestyle. It has become a standard measure in many economic analyses.
NNT analysis, although not actually a direct measure of cost, is a strong predictor for cost-effectiveness. For a particular medical intervention, an NNT study will calculate the number of individuals who need to be treated for a period of time (usually 5 years) to prevent the occurrence of one major morbid event.
The smaller the NNT, the more likely the treatment is to be cost-effective.
COST-EFFECTIVENESS AND THE TREATMENT OF HYPERLIPIDEMIA
Patients with established CHD have a high rate of expensive morbidity. 4, 6, 7, 9 Recent studies have demonstrated that the use of statins in the secondary preven- 4 During the 5.5 years of the study, patients who received simvastatin spent approximately 6000 fewer days in hospital (including coronary care units and acute medical wards) than patients treated with placebo ( Figure 1) . 10 Keeping a patient in hospital, especially in coronary or intensive care units, is extremely expensive. Therefore, any reduction in the number of days a patient is hospitalized (34% in the case of the 4S study) will result in considerable cost savings.
As previously discussed, the use of lipid-lowering strategies in the primary prevention of CHD will inevitably be less cost-effective than their use in the secondary prevention of CHD because patients at less risk provide less potential for offsetting costs. The difference in cost-effectiveness between primary and secondary prevention strategies is well illustrated by NNT analysis (Table 2 ). In the West of Scotland Coronary Prevention Study (WOSCOPS), 5 a primary CHD prevention trial of pravastatin in hypercholesterolemic men (total cholesterol ϭ 272 mg/dL [7.0 mmol/L]), approximately 40 men needed to be treated for 5 years to prevent one CHD death or nonfatal myocardial infarction (MI). By comparison, in the 4S trial, only 10 to 16 patients needed to be treated for 5 years to prevent one cardiovascular event.
Formal pharmacoeconomic assessments of the 4S and WOSCOPS studies have been conducted and their results confirm that there is less return on treatment investment in the primary prevention of CHD than there is in the secondary prevention of CHD (Raikou, McMurray, and McGuire, unpublished data). [11] [12] [13] In the original analysis of 4S, performed by Jö nsson and colleagues, the estimated cost of simvastatin therapy per LYG as applied to the UK was only £5502. 11 Using data from WOSCOPS, however, Caro et al showed that the cost of statin therapy can rise to approximately £20,000 per LYG. 13 Notably, if the same WOSCOPS analysis is confined to patients at the highest risk of CHD (those who have an absolute risk of Ն 20% over 10 years and the type of patient that the Second Joint Task Force of European and other Societies on Coronary Prevention 14 recommends for intensive risk factor modification), then the cost per LYG drops to about £14,000. 13 These data indicate that primary prevention strategies for CHD can probably be made more acceptable, in terms of cost-effectiveness, by concentrating mainly on those individuals who are at the greatest risk.
FIGURE 1. Total days spent in hospital during the 4S study by placebo-treated patients and simvastatin-treated patients (data taken from reference 10). *Significantly different from placebo (P Ͻ .0001).

TABLE 2. ASSESSMENT OF THE BENEFITS OF VARIOUS CARDIOVASCULAR TREATMENTS IN TERMS OF NUMBER NEEDED TO TREAT (NNT)
Treatment Events Prevented
NNT for 5 Years to Prevent One Event
Although the use of statins in the secondary prevention of CHD may be more cost-effective than their use in primary prevention, how expensive is statin therapy when compared with other routine medical interventions? Table 3 shows a number of treatment strategies and their relative cost-effectiveness as measured by cost per QALY. As a generally agreed international standard, most countries will provide hemodialysis, or dialysis of some description, to patients with end-stage renal failure. It is commonly accepted that a treatment strategy that is more cost-effective than hemodialysis (approximately £26,500 per QALY) is acceptable. With an estimated cost per QALY of £5000 to £10,000, the use of statins to treat established CHD can, therefore, be considered an economically viable treatment.
COST-EFFECTIVENESS AND THE TREATMENT OF HYPERTENSION
Many physicians, including some cardiologists, fail to realize that elderly hypertensive patients are an extremely high-risk patient population whose condition is associated with high rates of morbidity. In fact, the rates of morbid cardiovascular events in elderly hypertensives are not dissimilar to those in patients with established cardiovascular disease and are considerably greater than in patients within other primary prevention CHD categories (Table 4 ). In addition to stroke and MI, elderly hypertensive patients are at particular risk from congestive heart failure (CHF), an extremely disabling disorder. 15, 16 Because stroke, MI, and CHF are all very expensive cardiovascular events to treat, the use of antihypertensive medications to reduce blood pressure in the elderly provides immense potential to offset costs.
Once again, by using NNT analysis as a surrogate for cost-effectiveness, the economic benefits of treating hypertension in the elderly can be evaluated. Analyzing data from the Swedish Trial in Old Patients with Hypertension (STOP Hypertension), 15 a randomized trial comparing antihypertensive therapy with placebo, it has been estimated that only six patients would need to be treated for 5 years to prevent one major cardiovascular event. In the Systolic Hypertension in the Elderly Program (SHEP), 16 another placebo-controlled trial of antihypertensive therapy, one major cardiovascular event was prevented for every 18 patients treated for 5 years. These NNT values for the STOP and SHEP trials compare favorably with other secondary preventive therapies (Table 2) .
Formal pharmacoeconomic analysis of the STOP study supports the notion that the treatment of high blood pressure in older individuals is a highly costeffective strategy. 17 For male patients, the cost per LYG was estimated to be about £500 (Table 5 ). This value is one of the lowest cost-effectiveness ratios observed for any treatment in cardiovascular medicine, or indeed in any other branch of medicine, and may in part be due to the fact that the STOP study used an inexpensive thiazide diuretic. In contrast, the cost per LYG for antihypertensive treatment in a 40-year-old man is approxi- mately 100 times as much, at £49,000, 18 indicating that the treatment of younger hypertensives is a far greater drain on healthcare resources.
Care should be exercised when drawing conclusions from economic analyses conducted by different research groups, especially if they have employed different methods. However, three of the cost-effectiveness analyses listed in Table 5 were conducted by the same group 11, 17, 18 and the fourth, the analysis of the WOSCOPS study, 13 followed similar principles. On this basis, it is reasonable to conclude from these data that antihypertensive treatment in the elderly is more cost-effective than in the young and compares favorably with other secondary and primary preventive strategies for the treatment of CHD.
CONCLUSIONS
In comparison with other medical therapeutic strategies, and, in particular, with other cardiovascular interventions, the treatment of hypertensive patients and individuals with hypercholesterolemia is acceptably cost-effective. When the treatment is aimed at high-risk patients, such as elderly hypertensives or patients with established CHD, then blood-pressurelowering and lipid-lowering regimes become even more cost-effective. Thus, in the primary prevention setting and when considering individuals with multiple-risk factors, there is no convincing economic argument against treating these individuals to the best of our abilities. 
